Home

EpidEMcat is the study of the epidemiology of Multiple Sclerosis in Catalonia. It aims to characterize the disease at a population level in terms of incidence, prevalence, geographical distribution and evolution over time. These results are useful from a scientific and health management point of view and allows us to compare our region with others at a global level.

 The epidEMcat, was launched in June 2008 and is led jointly by the CEM-Cat (Multiple Sclerosis Center of Catalonia) and the Epidemiology Unit of the Hospital Vall d’Hebron and has the support of the Department of Salut de la Generalitat de Catalunya and the Multiple Sclerosis Foundation (FEM). EPIDEMCAT has the scientific advice of the CEM-Cat's Medical Advisory Board represented  by neurologists specializied in the management of MS in Catalonia.

 

Epidemiology


Highlights

There are no translations available.

Desde el pasado 20 de marzo el Registro EPIDEMCAT permite introducir pacientes prevalentes, es decir, aquellos con inicio de los síntomas antes de 2009 para las formas en brotes y antes del 2006 para las fomas de inicio progresivo. De esta forma, el Registro será completo, permitiendo conocer el impacto global de la enfermedad en Catalunya. Para facilitar la identificación de los pacientes, se ha sustituído la calve identificativa DNI por el CIP.

More news
 
There are no translations available.

El pasado mes de octubre de 2012 se celebró una reunión de trabajo con los participantes en el Registro con una doble finalidad: dar a conocer los datos trascurridos 3 años de funcionamiento y explorar opciones de mejora y expansión del registro. Para más información consultar acta reunión.

More news
 

By january 2012, The MS Registry of Catalonia includes over 600 patients.

More news
 

An European Registry of MS (EUReMS) is starting. The European Multiple Sclerosis Platform (EMSP) is coordinating the project EUReMS, carried out by a multidisciplinary team and funded from the European Commission. The CEM-Cat has been selected by the European Multiple Sclerosis Platform as one of the centers participating in the project. Learn more.

More news